JAZZ Stock Jazz Pharmaceuticals (JAZZ, $170.81) price moved above its 50-day Moving Average on January 14, 2026

GET DAILY SIGNALS

Get AI intraday signals

JAZZ - Jazz Pharmaceuticals plc

Moving Avg. signal

View

Odds of UP Trend

Price: $170.81

Daily change: +$8.38 (+5.16%)

Daily volume: 1.8M

Capitalization: $10.4B

Industry: Biotechnology

This price move could indicate a change in the trend, and may be a buy signal for investors. A.I.dvisor found 55 similar cases, and were successful. Based on this data, the odds of success are

JAZZ in upward trend: price rose above 50-day moving average on January 14, 2026

JAZZ moved above its 50-day moving average on January 14, 2026 date and that indicates a change from a downward trend to an upward trend. In of 55 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 63 cases where JAZZ's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JAZZ advanced for three days, in of 292 cases, the price rose further within the following month. The odds of a continued upward trend are .

JAZZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JAZZ as a result. In of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. JAZZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.622) is normal, around the industry mean (27.929). P/E Ratio (15.380) is within average values for comparable stocks, (51.397). JAZZ's Projected Growth (PEG Ratio) (4.188) is slightly higher than the industry average of (1.899). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (2.509) is also within normal values, averaging (329.547).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JAZZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.